Sonoma Pharmaceuticals (SNOA) Other Non-Current Liabilities (2011 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Other Non-Current Liabilities of $5.6 million for Q1 2026, up 8.21% year-over-year from $5.1 million in Q1 2025, and up 1.81% quarter-over-quarter from $5.5 million in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $5.6 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 8.21% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $5.6 million (up 8.21% YoY), while the FY2026 annual figure was $5.6 million, up 8.21% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $5.6 million, up from $5.5 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $5.6 million in Q1 2026, with the low at $3.8 million in Q1 2022.
- The 5-year median for Other Non-Current Liabilities is $4.7 million (2024), against an average of $4.7 million.
- The sharpest annual moves came in 2023 and 2026: Other Non-Current Liabilities climbed 12.06% in 2023, then gained 8.21% in 2026.
- Sonoma Pharmaceuticals' Other Non-Current Liabilities stood at $4.1 million in 2022, then rose by 12.06% to $4.6 million in 2023, then increased by 9.69% to $5.0 million in 2024, then advanced by 8.52% to $5.5 million in 2025, then gained by 1.81% to $5.6 million in 2026.
- Business Quant data shows SNOA's Other Non-Current Liabilities at $5.6 million in Q1 2026, $5.5 million in Q4 2025, and $5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.63 Mn |
| Mar 31, 2026 | 5.56 Mn |
| Dec 31, 2025 | 5.47 Mn |
| Sep 30, 2025 | 5.36 Mn |
| Jun 30, 2025 | 5.25 Mn |
| Mar 31, 2025 | 5.14 Mn |
| Dec 31, 2024 | 5.04 Mn |
| Sep 30, 2024 | 4.93 Mn |
| Jun 30, 2024 | 4.82 Mn |
| Mar 31, 2024 | 4.71 Mn |
| Dec 31, 2023 | 4.59 Mn |
| Sep 30, 2023 | 4.47 Mn |
| Jun 30, 2023 | 4.36 Mn |
| Mar 31, 2023 | 4.24 Mn |
| Dec 31, 2022 | 4.10 Mn |
| Sep 30, 2022 | 4.01 Mn |
| Jun 30, 2022 | 3.93 Mn |
| Mar 31, 2022 | 3.84 Mn |
| Dec 31, 2021 | 3.75 Mn |
| Sep 30, 2021 | 3.66 Mn |